Kedudukan dalam Saham
#12593
CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery,... CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.
Harga Saham
$9.09
Disegerakkan terakhir: 2023-06-23
Perubahan (1 tahun)
0.00%
Perdagangan CTI BioPharma Corp. (CTIC)
Harga CTIC dengan permodalan pasaran b
Modal pasaran bagi CTI BioPharma Corp.(CTIC)
Modal Pasaran: $567.77M
Sehingga August 2026, CTI BioPharma Corp. mempunyai modal pasaran sebanyak $567.77M. Ini menjadikan CTI BioPharma Corp. syarikat ke-12593rd paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran CTI BioPharma Corp. dari 1997 hingga 2026
CTIC berbanding dengan 5 teratas yang paling popular stocks
| Harga CTIC |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.264T
|
+927,011.86%
|
|
|
|
|
$4.701T
|
+827,923.98%
|
|
|
|
|
$4.177T
|
+735,615.87%
|
|
|
|
|
$3.817T
|
+672,249.31%
|
|
|
|
|
$2.866T
|
+504,740.75%
|
